Praluent drug class
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Praluent Drug Class: PCSK9 Inhibitors
Introduction to Praluent (Alirocumab)
Praluent, also known by its generic name alirocumab, is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi. It has been approved by the US Food and Drug Administration (FDA) as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
Mechanism of Action: PCSK9 Inhibition
Praluent belongs to a new class of drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 is an enzyme that plays a crucial role in cholesterol metabolism by regulating the number of LDL receptors on the liver. By binding to PCSK9, alirocumab prevents it from degrading LDL receptors, thereby increasing the liver's ability to remove LDL-C from the blood .
Clinical Efficacy and Usage
LDL-C Reduction
Clinical trials have demonstrated that alirocumab significantly reduces LDL-C levels. In the ODYSSEY clinical trial program, alirocumab was shown to lower LDL-C by 45-62% compared to placebo, with sustained efficacy over long-term treatment periods . This reduction is particularly beneficial for patients with hypercholesterolemia, including those with HeFH and nonfamilial hypercholesterolemia (nonFH), as well as those with mixed dyslipidemia.
Combination with Statins
Alirocumab can be used both as monotherapy and in combination with statin therapy. It is especially useful for patients who are statin-intolerant or those who do not achieve target LDL-C levels with statins alone . The drug is administered via subcutaneous injection every two weeks, with doses of 75 or 150 mg.
Safety and Tolerability
Alirocumab has been generally well tolerated in clinical trials, with a safety profile comparable to placebo. There were no significant increases in muscle-related adverse events, which are commonly associated with statin therapy . This makes alirocumab a valuable option for patients who experience statin intolerance.
Market and Legal Landscape
Praluent was the first PCSK9 inhibitor to be approved, followed closely by Amgen's Repatha (evolocumab). The introduction of PCSK9 inhibitors has been a significant advancement in the management of hyperlipidemia, offering a potent alternative to traditional statin therapy . However, the high cost of these specialty medications poses a challenge for healthcare payers.
Conclusion
Praluent (alirocumab) represents a significant advancement in the treatment of hypercholesterolemia, particularly for patients who are statin-intolerant or require additional LDL-C lowering. As a PCSK9 inhibitor, it offers a novel mechanism of action that effectively reduces LDL-C levels and has a favorable safety profile. While the high cost remains a concern, the clinical benefits of alirocumab make it a valuable option in the management of cardiovascular risk.
Sources and full results
Most relevant research papers on this topic